The cerebrospinal fluid HIV risk score for assessing central nervous system activity in persons with HIV

American Journal of Epidemiology

Volumn 180, Issue 3, 2014, Pages 297-307

  Hammond, Edward R ^a,b   Crum, Rosa M ^a,b   Treisman, Glenn J ^b   Mehta, Shruti H ^a   Marra, Christina M ^c   Clifford, David B ^d   Morgello, Susan ^e   Simpson, David M ^e   Gelman, Benjamin B ^f   Ellis, Ronald J ^g   Grant, Igor ^h   Letendre, Scott L ⁱ   McArthur, Justin C ^a,b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f University of Texas Medical Branch School of Medicine   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

central nervous system; cerebrospinal fluid; cerebrospinal fluid human immunodeficiency virus risk score; human immunodeficiency virus; prediction model

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS;

CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID HUMAN IMMUNODEFICIENCY VIRUS RISK SCORE; HUMAN IMMUNODEFICIENCY VIRUS; PREDICTION MODEL;

ADULT; ALGORITHMS; ANTI-RETROVIRAL AGENTS; CENTRAL NERVOUS SYSTEM; DRUG THERAPY, COMBINATION; FEMALE; HIV; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; MALE; PROBABILITY; RISK; RNA, VIRAL; VIRAL LOAD;

EID: 84905671288     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwu098     Document Type: Article

References (47)

1. Brodt HR, Kamps BS, Gute P, et al. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS. 1997;11(14):1731-1738
2. Sacktor N, McDermott MP, Marder K, et al. HIV-Associated cognitive impairment before and after the advent of combination therapy. J Neurovirol. 2002;8(2):136-142
3. Woods SP, Moore DJ, Weber E, et al. Cognitive neuropsychology of HIV-Associated neurocognitive disorders. Neuropsychol Rev. 2009;19(2):152-168
4. McArthur JC. HIV dementia: An evolving disease. J Neuroimmunol. 2004;157(1-2):3-10
5. Robertson KR, Smurzynski M, Parsons TD, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS. 2007;21(14):1915-1921
6. Heaton RK, Marcotte TD, Mindt MR, et al. The impact of HIV-Associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc. 2004;10(3): 317-331
7. Ickovics JR, Hamburger ME, Vlahov D, et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: Longitudinal analysis from the HIV Epidemiology Research Study. JAMA. 2001;285(11): 1466-1474
8. Tozzi V, Balestra P, Serraino D, et al. Neurocognitive impairment and survival in a cohort of HIV-infected patients treated with HAART. AIDS Res Hum Retroviruses. 2005;21(8): 706-713
9. Spudich S, Gisslen M, Hagberg L, et al. Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden. J Infect Dis. 2011; 204(5):753-760
10. Letendre SL, Ellis RJ, Ances BM, et al. Neurologic complications of HIV disease and their treatment. Top HIV Med. 2010;18(2):45-55
11. Christo PP, Greco DB, Aleixo AW, et al. Factors influencing cerebrospinal fluid and plasma HIV-1 RNA detection rate in patients with and without opportunistic neurological disease during the HAART era. BMC Infect Dis. 2007;7:147
12. Canestri A, Lescure FX, Jaureguiberry S, et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis. 2010;50(5): 773-778
13. Edén A, Fuchs D, Hagberg L, et al. HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis. 2010;202(12): 1819-1825
14. Garvey LJ, Everitt A,Winston A, et al. Detectable cerebrospinal fluid HIV RNA with associated neurological deficits, despite suppression of HIV replication in the plasma compartment. AIDS. 2009;23(11):1443-1444
15. Schouten J, Cinque P, Gisslen M, et al. HIV-1 infection and cognitive impairment in the cART era: A review. AIDS. 2011; 25(5):561-575
16. European AIDS Clinical Society. Guidelines version 7.0. http://eacsociety.org/Portals/0/Guidelines-Online-131014.pdf. Published October 2013. Accessed March 24, 2014
17. Mind Exchange Working Group. Assessment, diagnosis, and treatment of HIV-Associated neurocognitive disorder: A consensus report of the Mind Exchange Program. Clin Infect Dis. 2013;56(7):1004-1017
18. Polis MA, Suzman DL, Yoder CP, et al. Suppression of cerebrospinal fluid HIV burden in antiretroviral naive patients on a potent four-drug antiretroviral regimen. AIDS. 2003;17(8): 1167-1172
19. Price RW, Yiannoutsos CT, Clifford DB, et al. Neurological outcomes in late HIV infection: Adverse impact of neurological impairment on survival and protective effect of antiviral therapy. AIDS Clinical Trial Group and Neurological AIDS Research Consortium study team. AIDS. 1999;13(13): 1677-1685
20. Ellis RJ, Moore DJ, Childers ME, et al. Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA. Arch Neurol. 2002; 59(6):923-928
21. Cysique LA, Waters EK, Brew BJ. Central nervous system antiretroviral efficacy in HIV infection: A qualitative and quantitative review and implications for future research. BMC Neurol. 2011;11:148
22. Strazielle N, Khuth ST, Ghersi-Egea JF. Detoxification systems, passive and specific transport for drugs at the blood-CSF barrier in normal and pathological situations. Adv Drug Deliv Rev. 2004;56(12):1717-1740
23. Heaton RK, Clifford DB, Franklin DR Jr, et al. HIV-Associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010; 75(23):2087-2096
24. Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care. 2000;12(3): 255-266
25. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008;65(1):65-70
26. Carey CL, Woods SP, Gonzalez R, et al. Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol. 2004; 26(3):307-319
27. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Revised 4th ed. Washington, DC: American Psychiatric Association; 2000
28. Steer RA, Clark DA, Beck AT, et al. Common and specific dimensions of self-reported anxiety and depression: The BDI-II versus the BDI-IA. Behav Res Ther. 1999;37(2): 183-190
29. Royston P, Moons KG, Altman DG, et al. Prognosis and prognostic research: Developing a prognostic model. BMJ. 2009;338:b604
30. Sauerbrei W, Royston P, Binder H. Selection of important variables and determination of functional form for continuous predictors in multivariable model building. Stat Med. 2007; 26(30):5512-5528
31. Sullivan LM, Massaro JM, D'Agostino RB Sr. Presentation of multivariate data for clinical use: The Framingham Study risk score functions. Stat Med. 2004;23(10):1631-1660
32. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982; 143(1):29-36
33. Hosmer DW, Lemeshow S. Applied Logistic Regression. 2nd ed. New York, NY: Wiley; 2000
34. Van Houwelingen JC, Le Cessie S. Predictive value of statistical models. Stat Med. 1990;9(11):1303-1325
35. Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York, NY: Wiley; 1987
36. Donders AR, van Der Heijden GJ, Stijnen T, et al. Review: A gentle introduction to imputation of missing values. J Clin Epidemiol. 2006;59(10):1087-1091
37. Marra CM, Zhao Y, Clifford DB, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS. 2009;23(11):1359-1366
38. Moons KG, Royston P, Vergouwe Y, et al. Prognosis and prognostic research:What,why, and how?. BMJ. 2009;338:b375
39. Riley RD, Abrams KR, Sutton AJ, et al. Reporting of prognostic markers: Current problems and development of guidelines for evidence-based practice in the future. Br J Cancer. 2003;88(8):1191-1198
40. Peluso MJ, Ferretti F, Peterson J, et al. Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load. AIDS. 2012;26(14):1765-1774
41. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. http://www.aidsinfo.nih.gov/ ContentFiles/AdultandAdolescentGL.pdf. Updated February 12, 2013. Accessed March 24, 2014
42. Cruess DG, Douglas SD, Petitto JM, et al. Association of resolution of major depression with increased natural killer cell activity among HIV-seropositive women. Am J Psychiatry. 2005;162(11):2125-2130
43. Centers for Disease Control and Prevention (CDC). Racial/ethnic disparities in diagnoses of HIV/AIDS-33 states, 2001-2004. MMWR Morb Mortal Wkly Rep 2006;55(5): 121-125
44. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature. 1996;382(6593): 722-725
45. Tedaldi EM, Absalon J, Thomas AJ, et al. Ethnicity, race, and gender. Differences in serious adverse events among participants in an antiretroviral initiation trial: Results of CPCRA 058 (FIRST Study). J Acquir Immune Defic Syndr. 2008;47(4):441-448
46. Gebo KA, Fleishman JA, Conviser R, et al. Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J Acquir Immune Defic Syndr. 2005;38(1):96-103
47. Cysique LA, Murray JM, Dunbar M, et al. A screening algorithm for HIV-Associated neurocognitive disorders. HIV Med. 2010;11(10):642-649